trial · primary record
Radiation
Breast Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 88 |
| Primary completion | 2026-12-31 |
| Primary endpoint | Acute Toxicity Will be Measured by Evaluating the Number of Patients Who Experience Grade II-III Dermatitis Within 60 Days of Radiation Therapy. |
| Registry ID | NCT02917421 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:25.797Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02917421
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.